GlassScriptPhysician profile
Saira Saad
NPI 1609352061
$47,840.53
in general payments reported to CMS, 2019-2025
16 companies · $9,993 in 2025
The $9,993 reported for 2025 was more than what 88% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $58.34 · 2021: $132 · 2022: $861 · 2023: $58.00 · 2024: $318 · 2025: $9,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,100 · Travel and Lodging: $2,338 · Food and Beverage: $1,643 · Education: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,100.00 |
| Travel and Lodging | $2,337.81 |
| Food and Beverage | $1,643.03 |
| Education | $1,288.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $35,602.09 | 2019 | |
| Amneal Pharmaceuticals LLC | $6,693.70 | 2019-2025 | Crexont, Ongentys |
| Abbott Laboratories | $1,886.36 | 2019-2025 | Infinity, Proclaim |
| Medtronic, INC. | $1,367.28 | 2021-2025 | Percept PC Brainsense, Sensight |
| Boston Scientific Corporation | $1,148.31 | 2019-2025 | Vercise, General - Dbs |
| Acorda Therapeutics, INC | $408.34 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $254.86 | 2025 | Dysport |
| Merz North America, INC. | $120.00 | 2019 | |
| Mdd US Operations, LLC | $103.56 | 2019-2025 | Apokyn |
| Astrazeneca Pharmaceuticals LP | $92.48 | 2024 | Lokelma |
| Biohaven Pharmaceuticals, INC. | $49.58 | 2021 | |
| Abbvie INC. | $47.28 | 2025 | |
| Neurocrine Biosciences, INC. | $18.93 | 2019 | |
| Csl Behring | $17.33 | 2020 | |
| Kyowa Kirin, INC. | $17.03 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $13.40 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saira Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.